封面
市場調查報告書
商品編碼
1738266

分子腫瘤診斷市場-全球產業規模、佔有率、趨勢、競爭、機會和預測,按產品類型、技術、應用、癌症類型、最終用戶、地區和競爭細分,2020-2030 年

Molecular Oncology Diagnostics Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, Segmented By Product Type, By Technology, By Application, By Cancer Type, By End User, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年,全球分子腫瘤診斷市場規模達35.4億美元,預計2030年將達78.4億美元,預測期內複合年成長率為14.17%。由於慢性病(尤其是癌症)發生率的上升,市場正在迅速擴張,這推動了對先進診斷解決方案的需求。分子腫瘤診斷是指用於在分子層面檢測癌症的專門檢測,識別指示疾病存在的遺傳物質、蛋白質和生物標記。這種方法有助於早期發現、標靶治療和改善患者預後。認知度的提高、新一代定序 (NGS) 等技術的進步以及對個人化醫療的持續投資,都促進了市場的成長。此外,嚴格的監管框架和全球向精準腫瘤學的轉變,正在推動分子診斷平台的創新。隨著全球醫療保健系統強調早期發現和高效的疾病管理,分子腫瘤診斷市場在已開發地區和新興地區都將持續擴張。

市場概覽
預測期 2026-2030
2024年市場規模 35.4億美元
2030年市場規模 78.4億美元
2025-2030 年複合年成長率 14.17%
成長最快的領域 軟體
最大的市場 北美洲

關鍵市場促進因素

全球癌症發生率上升,早期檢測需求增加

主要市場挑戰

先進診斷技術成本高且難以取得

主要市場趨勢

人工智慧和機器學習在分子診斷中的整合

目錄

第 1 章:產品概述

第2章:研究方法

第3章:執行摘要

第4章:顧客之聲

第5章:全球分子腫瘤診斷市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依產品類型(儀器、試劑盒和分析、軟體)
    • 依技術(螢光原位雜合技術 (FISH)、次世代定序 (NGS)、聚合酶鍊式反應 (PCR)、免疫組織化學 (IHC)、流式細胞儀和其他技術)
    • 按應用(研究、臨床)
    • 依癌症類型{實體腫瘤(乳腺癌、卵巢癌、前列腺癌、肺癌、大腸直腸癌和其他實體腫瘤)、血癌(淋巴瘤、白血病、多發性骨髓瘤和其他血液系統惡性腫瘤)}
    • 按最終用戶(醫院和診斷中心、參考實驗室、製藥和生物技術公司、學術和研究機構)
    • 按地區(北美、歐洲、亞太、南美、中東和非洲)
    • 按公司分類(2024)
  • 市場地圖
    • 依產品類型
    • 依技術
    • 按應用
    • 按癌症類型
    • 按最終用戶
    • 按地區

第6章:北美分子腫瘤診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美:國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章:歐洲分子腫瘤診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲:國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章:亞太地區分子腫瘤診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區:國家分析
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲

第9章:南美洲分子腫瘤診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲:國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章:中東與非洲分子腫瘤診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA:國家分析
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非

第 11 章:市場動態

  • 驅動程式
  • 挑戰

第 12 章:市場趨勢與發展

  • 合併與收購(如有)
  • 產品發布(如有)
  • 最新動態

第 13 章:波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品/服務的威脅

第 14 章:全球分子腫瘤診斷市場:SWOT 分析

第 15 章:競爭格局

  • Sysmex Corporation
  • F. Hoffmann-La Roche Ltd.
  • Myriad Genetics, Inc.
  • HTG Molecular Diagnostics, Inc.
  • Danaher Corporation
  • QIAGEN NV
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Illumina, Inc.
  • Bayer AG

第 16 章:策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 15019

The Global Molecular Oncology Diagnostics Market was valued at USD 3.54 billion in 2024 and is projected to reach USD 7.84 billion by 2030, growing at a CAGR of 14.17% during the forecast period. The market is expanding rapidly due to the rising incidence of chronic diseases, particularly cancer, which is driving the demand for advanced diagnostic solutions. Molecular oncology diagnostics refer to specialized tests used to detect cancer at the molecular level, identifying genetic materials, proteins, and biomarkers that signal the presence of disease. This approach supports early detection, targeted therapy, and improved patient outcomes. Increased awareness, advances in technology such as next-generation sequencing (NGS), and growing investments in personalized medicine are all contributing to market growth. In addition, stringent regulatory frameworks and a global shift toward precision oncology are encouraging innovation in molecular diagnostic platforms. As healthcare systems worldwide emphasize early detection and efficient disease management, the molecular oncology diagnostics market is poised for sustained expansion across developed and emerging regions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 3.54 Billion
Market Size 2030USD 7.84 Billion
CAGR 2025-203014.17%
Fastest Growing SegmentSoftware
Largest MarketNorth America

Key Market Drivers

Increasing Global Cancer Incidence and Demand for Early Detection

The rising global prevalence of cancer is a major factor propelling growth in the molecular oncology diagnostics market. According to the World Health Organization (WHO), nearly 10 million people died from cancer in 2020, with the incidence rate expected to rise by 47% by 2040, reaching over 28 million new cases annually. This alarming increase has led to a heightened focus on early detection and precision diagnostics to improve treatment outcomes and reduce healthcare burdens. Molecular diagnostics offer a pathway for identifying cancer-related mutations, chromosomal changes, and gene expression profiles even before clinical symptoms appear. Technologies like PCR, NGS, and microarrays are pivotal in enabling personalized treatment strategies and enhancing prognosis accuracy. Governments and research bodies are investing heavily in cancer diagnostics infrastructure; for example, the U.S. National Cancer Institute allocated over $7 billion in 2023 for cancer research, with a strong emphasis on molecular diagnostic tools. These developments underscore the growing importance of molecular oncology diagnostics in combating the global cancer burden.

Key Market Challenges

High Cost and Limited Accessibility of Advanced Diagnostic Technologies

Despite technological progress, the high cost of molecular oncology diagnostics remains a critical barrier to widespread adoption. Advanced testing methods like next-generation sequencing and multiplex PCR panels require expensive reagents, equipment, and skilled professionals, making them inaccessible in many low- and middle-income countries. A single NGS test can cost between $1,000 and $5,000, limiting affordability for patients and straining underfunded healthcare systems. Furthermore, insufficient diagnostic infrastructure, particularly in rural areas, exacerbates disparities in healthcare access. Challenges include a lack of molecular pathology labs, inadequate cold chain systems, and a shortage of trained personnel. Even in developed nations, inconsistent reimbursement policies hinder the adoption of newer molecular tests. According to the World Bank, healthcare expenditure in low-income nations averages about 5% of GDP, compared to more than 10% in high-income countries. This disparity underscores the urgent need for policy support, public-private partnerships, and cost-reduction strategies to bridge the accessibility gap in molecular diagnostics.

Key Market Trends

Integration of Artificial Intelligence and Machine Learning in Molecular Diagnostics

A transformative trend in the molecular oncology diagnostics market is the integration of artificial intelligence (AI) and machine learning (ML) technologies to streamline and enhance genomic data analysis. As diagnostic platforms generate increasingly complex datasets, AI and ML provide tools to analyze patterns, classify cancer subtypes, and predict patient responses more accurately and rapidly than manual methods. These technologies can process thousands of variants simultaneously, identifying clinically relevant mutations and helping in treatment selection. Deep learning models are also being used to enhance the accuracy of image-based diagnostics and to interpret multi-omics data in real-time. Governments are supporting AI development through major funding initiatives, such as the NIH's Bridge2AI program in the U.S. and the UK's Industrial Strategy Challenge Fund. These efforts are catalyzing the adoption of AI-driven diagnostics, making molecular oncology testing more efficient, scalable, and accessible across the globe.

Key Market Players

  • Sysmex Corporation
  • F. Hoffmann-La Roche Ltd.
  • Myriad Genetics, Inc.
  • HTG Molecular Diagnostics, Inc.
  • Danaher Corporation
  • QIAGEN N.V.
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Illumina, Inc.
  • Bayer AG

Report Scope:

In this report, the Global Molecular Oncology Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Molecular Oncology Diagnostics Market, By Product Type:

  • Instruments
  • Kits and Assays
  • Software

Molecular Oncology Diagnostics Market, By Technology:

  • Fluorescence In-Situ Hybridization (FISH)
  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Flow Cytometry
  • Other Technologies

Molecular Oncology Diagnostics Market, By Application:

  • Research
  • Clinical

Molecular Oncology Diagnostics Market, By Cancer Type:

  • Solid Tumor (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Other Solid Tumors)
  • Blood Cancers (Lymphoma, Leukemia, Multiple Myeloma, and other Hematological Malignancies)

Molecular Oncology Diagnostics Market, By End User:

  • Hospitals and Diagnostic Centers
  • Reference Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes

Molecular Oncology Diagnostics Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Molecular Oncology Diagnostics Market.

Available Customizations:

Global Molecular Oncology Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Molecular Oncology Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Instruments, Kits and Assays, Software)
    • 5.2.2. By Technology (Fluorescence In-Situ Hybridization (FISH), Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Flow Cytometry, and Other Technologies)
    • 5.2.3. By Application (Research, Clinical)
    • 5.2.4. By Cancer Type {Solid Tumor (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Other Solid Tumors), Blood cancers (Lymphoma, Leukemia, Multiple Myeloma, and other Hematological Malignancies)}
    • 5.2.5. By End User (Hospitals and Diagnostic Centers, Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes)
    • 5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East, and Africa)
    • 5.2.7. By Company (2024)
  • 5.3. Market Map
    • 5.3.1. By Product Type
    • 5.3.2. By Technology
    • 5.3.3. By Application
    • 5.3.4. By Cancer Type
    • 5.3.5. By End User
    • 5.3.6. By Region

6. North America Molecular Oncology Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By Cancer Type
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Molecular Oncology Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By Cancer Type
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Molecular Oncology Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By Cancer Type
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Molecular Oncology Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By Cancer Type
        • 6.3.3.2.5. By End User

7. Europe Molecular Oncology Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By Cancer Type
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Molecular Oncology Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By Cancer Type
        • 7.3.1.2.5. By End User
    • 7.3.2. France Molecular Oncology Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By Cancer Type
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Molecular Oncology Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By Cancer Type
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Molecular Oncology Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By Cancer Type
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Molecular Oncology Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By Cancer Type
        • 7.3.5.2.5. By End User

8. Asia-Pacific Molecular Oncology Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By Cancer Type
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Molecular Oncology Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By Cancer Type
        • 8.3.1.2.5. By End User
    • 8.3.2. Japan Molecular Oncology Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By Cancer Type
        • 8.3.2.2.5. By End User
    • 8.3.3. India Molecular Oncology Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By Cancer Type
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Molecular Oncology Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By Cancer Type
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Molecular Oncology Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By Cancer Type
        • 8.3.5.2.5. By End User

9. South America Molecular Oncology Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By Cancer Type
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Molecular Oncology Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By Cancer Type
        • 9.3.1.2.5. By End User
    • 9.3.2. Argentina Molecular Oncology Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By Cancer Type
        • 9.3.2.2.5. By End User
    • 9.3.3. Colombia Molecular Oncology Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By Cancer Type
        • 9.3.3.2.5. By End User

10. Middle East and Africa Molecular Oncology Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By Cancer Type
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE Molecular Oncology Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By Cancer Type
        • 10.3.1.2.5. By End User
    • 10.3.2. Saudi Arabia Molecular Oncology Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By Cancer Type
        • 10.3.2.2.5. By End User
    • 10.3.3. South Africa Molecular Oncology Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By Cancer Type
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products/Services

14. Global Molecular Oncology Diagnostics Market: SWOT Analysis

15. Competitive Landscape

  • 15.1. Sysmex Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. F. Hoffmann-La Roche Ltd.
  • 15.3. Myriad Genetics, Inc.
  • 15.4. HTG Molecular Diagnostics, Inc.
  • 15.5. Danaher Corporation
  • 15.6. QIAGEN N.V.
  • 15.7. Bio-Rad Laboratories, Inc.
  • 15.8. Agilent Technologies, Inc.
  • 15.9. Illumina, Inc.
  • 15.10. Bayer AG

16. Strategic Recommendations

17. About Us & Disclaimer